A Randomized, Single-blind, Parallel-group Study to Evaluate the Effects of TS-134 on Ketamine-induced BOLD Signals in Resting fMRI in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 03 May 2018
Price : $35 *
At a glance
- Drugs TS 134 (Primary) ; Ketamine
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Taisho Pharmaceutical
- 27 Apr 2018 Status changed from recruiting to completed.
- 01 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Mar 2018.
- 01 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Mar 2018.